An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®). In this study the patients will be assigned by chance to receive either the new drug or a chemotherapy treatment (Navelbine®). Treatment will continue as long as the cancer does not worsen and the patient wishes to continue in the study. The study will recruit approximately 66 patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Diagnosed with mesothelioma
- Previously treated with only one course of chemotherapy for mesothelioma
- No previous treatment with vinorelbine
- No serious heart problems within the last 3 months
Exclusion criteria
- Serious abnormal laboratory values
- Severe or uncontrolled disease or condition as judged by the Investigator
- Pregnant or breast-feeding women
- Other cancers within the last 5 years
- Major surgery or radiation therapy within 4 weeks prior to starting study therapy
- Receipt of any investigational agents within 30 days prior to commencing study treatment.
Trial design
Primary purpose
Allocation
Interventional model
Masking
25 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal